AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38186641
Drug: New long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New long-acting insulin analog
Trial: 38187149
Drug: Moderate-to-severe anemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-to-severe anemia (Hb <11 g/dL for men and <10 g/dL for women)
Trial: 38187149
Drug: No anemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anemia (Hb ≥13 g/dL for men and ≥12 g/dL for women)
Trial: 38187149
Drug: Mild anemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild anemia (Hb 11-13 g/dL for men and 10-12 g/dL for women)
Trial: 38187863
Drug: Telazorlimab 300
RxNorm normalized name: Telazorlimab
DrugBank: Telazorlimab (DB16374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telazorlimab 300 mg every 2 weeks (part 1)
Trial: 38187863
Drug: Telazorlimab 600
RxNorm normalized name: Telazorlimab
DrugBank: Telazorlimab (DB16374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telazorlimab 600 mg every 2 weeks (part 2)
Trial: 38188262
Drug: Vaccine counseling
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine counseling in ICU recovery clinics (ICU-RCs)
Trial: 38188344
Drug: Local thermotherapy
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local thermotherapy via an electric heat pad in the thorax (target temperature range 39.5–42°C) continuously for 90 minutes, twice daily, for 5 days
Trial: 38188467
Drug: TQB2450 (1-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 (1-30 mg/kg, intravenous once every 3 weeks)
Trial: 38188690
Drug: Leritrelvir 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leritrelvir 400 mg TID for 5 days
Trial: 38189125
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to community-based rehabilitation (physical, occupational, or speech therapy) at discharge
Trial: 38189125
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to physical therapy
Trial: 38189125
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to occupational therapy
Trial: 38189125
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to speech therapy
Trial: 38190077
Drug: PP1M (fixed-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PP1M (fixed-dose, 50, 75, 100, or 150 mg eq.)
Trial: 38190077
Drug: PP3M (fixed-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PP3M (fixed-dose, 175, 263, 350, or 525 mg eq.)
Trial: 38190136
Drug: Argatroban (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argatroban (60 mg per day for 2 days, followed by 20 mg per day for 5 days) in addition to standard therapy (oral mono or dual antiplatelet therapy)
Trial: 38190242
Drug: RE-PACT intervention
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RE-PACT intervention (action planning, rapid clinical response, weekly SMS text messaging surveillance)
Trial: 38190642
Drug: Lopinavir/Ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/Ritonavir (LPV/r) oral solution
Trial: 38191245
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment including reduction and fixation of the syndesmosis
Trial: 38191245
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment with an orthosis
Trial: 38191317
Drug: MedSUS app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: MedSUS app (provides general information about medications)
Trial: 38191436
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving no treatment
Trial: 38191436
Drug: Simplified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simplified treatment receiving 1 sachet of RUTF daily until WAZ ≥-3 for 2 visits
Trial: 38191436
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment receiving RUTF according to WHZ category
Trial: 38191449
Drug: L-carnitine 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine 1000 mg (3 tablets daily) for 6 weeks
Trial: 38191449
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 tablets daily) for 6 weeks
Trial: 38191613
Drug: Atezolizumab monotherapy
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab monotherapy followed by four cycles of atezolizumab plus docetaxel, oxaliplatin and capecitabine
Trial: 38192233
Drug: Tildrakizumab 100
RxNorm normalized name: tildrakizumab 100 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tildrakizumab 100 mg subcutaneously at weeks 0 and 4
Trial: 38192233
Drug: Tildrakizumab 100
RxNorm normalized name: tildrakizumab 100 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tildrakizumab 100 mg subcutaneously every 12 weeks after week 12
Trial: 38192592
Drug: Durvalumab 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 1500 mg every 28 days until progression or unacceptable toxicity
Trial: 38193158
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT), 2 to 4 sessions
Trial: 38194016
Drug: Serplulimab (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serplulimab (0.3, 1.0, 3.0, and 10.0 mg/kg every 2 weeks in 28-day cycles for up to 2 years)
Trial: 38194047
Drug: Dupilumab (200/300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab (200/300 mg) every 4 weeks for 16 weeks
Trial: 38194162
Drug: Efbemalenograstim alfa
RxNorm normalized name: efbemalenograstim alfa
DrugBank: Efbemalenograstim alfa (DB18704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efbemalenograstim alfa (80, 240, or 320 µg/kg for TC; 240 or 320 µg/kg for TAC)
Trial: 38194231
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by chemoradiation
Trial: 38194231
Drug: Chemoradiation followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemoradiation followed by consolidation chemotherapy
Trial: 38194233
Drug: Curative-intent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curative-intent therapy for colorectal cancer
Trial: 38194233
Drug: Functional Assessment
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Assessment of Cancer Therapy-General (rapid version) score increase
Trial: 38194272
Drug: PfSPZ Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PfSPZ Vaccine (5 doses over 28 days)
Trial: 38194616
Drug: Adjuvant Abemaciclib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant Abemaciclib plus endocrine therapy
Trial: 38194616
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (endocrine therapy alone)
Trial: 38194692
Drug: Tisagenlecleucel infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tisagenlecleucel infusion (0.6 × 10^8-6 × 10^8 chimeric antigen receptor-positive viable T cells)
Trial: 38195076
Drug: Concurrent tumor-treating
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent tumor-treating fields (TTFields) with radiation and temozolomide
Trial: 38195076
Drug: Bevacizumab treatment
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab treatment after recurrence
Trial: 38195322
Drug: Mosunetuzumab (intravenous)
RxNorm normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosunetuzumab (intravenous) - 1 mg on Day 1, 2 mg on Day 8, 60 mg on Day 15/Cycle 2 Day 1, and 30 mg from Cycle 3 Day 1 onwards for a median of eight 21-day cycles.
Trial: 38195348
Drug: 150-mg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150-mg IV infusion of lefamulin
Trial: 38195348
Drug: 600-mg oral
RxNorm normalized name: ubidecarenone 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600-mg oral tablet of lefamulin
Trial: 38195568
Drug: Dietary sulfur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary sulfur amino acid restriction (SAAR) ~ 2 g/day
Trial: 38195568
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group ~ 5.6 g/day sulfur amino acids
Trial: 38195600
Drug: HEARTS-aligned components
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEARTS-aligned components including training health workers, strengthening access to medications, risk-based management, team-based care, and electronic monitoring.
Trial: 38196092
Drug: Smoking (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking (daily and occasional)
Trial: 38196092
Drug: Tobacco use
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobacco use (daily, occasional, and snus)
Trial: 38196286
Drug: Dual Antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual Antiplatelet Therapy
Trial: 38702783
Drug: Mind-body intervention
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mind-body intervention as an adjunct to MOUD
Trial: 38196650
Drug: MOUD (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOUD (standard treatment)
Trial: 38196756
Drug: Polyphenol-enriched treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenol-enriched treatment (PET) lettuce
Trial: 38196889
Drug: Mepolizumab 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab 300 mg every 4 weeks for 52 weeks
Trial: 38196969
Drug: Treatment-as-usual (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (n = 47)
Trial: 38197000
Drug: Sustained-release pregabalin
RxNorm normalized name: pregabalin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release pregabalin tablet (YHD1119), once-daily dosing.
Trial: 38197040
Drug: Qualitative understanding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitative understanding of experiences related to cancer cachexia (CC) through semi-structured interviews
Trial: 38197040
Drug: Treatment recommendations
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment recommendations by oncologist for anorexia and weight loss
Trial: 38197815
Drug: Repotrectinib (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repotrectinib (160 mg daily for 14 days, then 160 mg twice daily)
Trial: 38197817
Drug: 500-mg daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-mg daily dose of calcium supplementation
Trial: 38197817
Drug: 1500-mg daily
RxNorm normalized name: glecaprevir
DrugBank: Glecaprevir (DB13879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1500-mg daily dose of calcium supplementation
Trial: 38197816
Drug: Acoramidis hydrochloride
RxNorm normalized name: acoramidis hydrochloride
DrugBank: Acoramidis (DB17999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acoramidis hydrochloride at a dose of 800 mg twice daily
Trial: 38197863
Drug: Short duration
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short duration of antiretroviral therapy (ART)
Trial: 38197938
Drug: Venetoclax and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax and azacitidine (Ven/Aza) maintenance therapy: Aza 36 mg/m2 intravenously on days 1 to 5, and Ven 400 mg by mouth on days 1 to 14 (42-day cycles × 8, or 28-day cycles × 12)
Trial: 38197938
Drug: Venetoclax and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax and azacitidine (Ven/Aza) maintenance therapy
Trial: 38198010
Drug: HRS-2261 (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-2261 (25, 100, 200, 400, 800, and 1200 mg)
Trial: 38198010
Drug: HRS-2261 (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-2261 (50, 200, and 400 mg)
Trial: 38198053
Drug: Proactive intravitreal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive intravitreal aflibercept (IVT-AFL) treatment regimens (fixed dosing or treat-and-extend)
Trial: 38198106
Drug: Carglumic acid
RxNorm normalized name: Carglumic Acid
DrugBank: Carglumic acid (DB06775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carglumic acid treatment for at least 1 year
Trial: 38198456
Drug: Therapy with
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy with placebo
Trial: 38199617
Drug: Oral challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral challenge with one of two strains of non-typhoidal
Trial: 38199626
Drug: Implementation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation of prescribing recommendations from the OPTICA medication review
Trial: 38199626
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in the number of long-term medications
Trial: 38199626
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in medication appropriateness (Medication Appropriateness Index)
Trial: 38199634
Drug: HOW R
RxNorm normalized name: R-348
DrugBank: R-348 (DB06321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOW R U? weekly volunteer-peer support telephone intervention
Trial: 38199634
Drug: HOW R
RxNorm normalized name: R-348
DrugBank: R-348 (DB06321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOW R U? delivered using a video-conferencing solution
Trial: 38199751
Drug: Target lesion
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target lesion revascularization (TLR) after percutaneous coronary intervention (PCI) with drug-eluting stents (DES)
Trial: 38199789
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (two uninterrupted rounds of ovarian stimulation with GnRH agonist triggering)
Trial: 38200171
Drug: Microneedling radiofrequency
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedling radiofrequency (RF) treatment continued monthly over 6 months after 2 months of conventional therapy.
Trial: 38200233
Drug: DFMO (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFMO (up to 9000 mg/m) with celecoxib, cyclophosphamide, and topotecan
Trial: 38200320
Drug: Aflibercept 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept 0.4 mg/eye
Trial: 38200325
Drug: Fentanyl 0.5-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 0.5-1 mcg/kg intravenously
Trial: 38200325
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline solution intravenously
Trial: 38203214
Drug: Single-agent regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single-agent regorafenib
Trial: 38203593
Drug: AAT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAT treatment
Trial: 38204364
Drug: Oral tramadol/dexketoprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tramadol/dexketoprofen (TRAM/DKP)
Trial: 38204364
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol + tramadol (PARA+TRAM)
Trial: 38205679
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of allogeneic adipose-derived mesenchymal stem cells (ADSCs) GXCPC1
Trial: 38206151
Drug: PLLA-SCA injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLLA-SCA injections (150 mg; 8 mL reconstitution in sterile water for injection) + 1 mL lidocaine hydrochloride (2%)
Trial: 38206151
Drug: PLLA-SCA injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLLA-SCA injections
Trial: 38206187
Drug: Doravirine (biological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine (biological cutoff 3.0)
Trial: 38206518
Drug: Biosimilars (TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosimilars (TNF inhibitors) - adalimumab (ADA), etanercept (ETA), infliximab (IFX)
Trial: 38206518
Drug: Biosimilars (TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosimilars (TNF inhibitors)
Trial: 38206614
Drug: Low-dose cohort
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cohort (4 Gy × 10 fractions + 25 Gy SABR boost, 5 Gy × 5 fractions)
Trial: 38206614
Drug: Intermediate-dose cohort
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose cohort (4 Gy × 10 fractions + 30 Gy SABR boost, 6 Gy × 5 fractions)
Trial: 38206614
Drug: High-dose cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cohort (4 Gy × 10 fractions + 35 Gy SABR boost, 7 Gy × 5 fractions)
Trial: 38206631
Drug: Mirtazapine 15
RxNorm normalized name: mirtazapine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine 15 mg for 2 weeks followed by 30 mg until week 8
Trial: 38206830
Drug: Lanreotide Autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide Autogel 120 mg plus Temozolomide (TMZ)
Trial: 38206830
Drug: Lanreotide Autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide Autogel 120 mg maintenance
Trial: 38206830
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (LAN plus TMZ)
Trial: 38206930
Drug: Varenicline (0.5‒2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (0.5‒2 mg) and Bupropion SR (150‒300 mg)
Trial: 38207208
Drug: mini-hyper-CVD plus
RxNorm normalized name: Hyper-Sal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mini-hyper-CVD plus venetoclax (200 mg or 400 mg daily)
Trial: 38207246
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care with proactive symptom assessment (peer volunteer weekly phone calls)
Trial: 38211601
Drug: Oral linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral linezolid (600 mg once per day for 5 days)
Trial: 38211601
Drug: Intramuscular benzathine
RxNorm normalized name: Cephapirin Benzathine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular benzathine penicillin G (single dose of 2.4 million international units)
Trial: 38211604
Drug: Linaclotide 72
RxNorm normalized name: LINACLOTIDE 72MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linaclotide 72 μg once daily for 12 weeks
Trial: 38211606
Drug: Subtyping-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subtyping-based therapy (nab-paclitaxel 100 mg/m2 in 28-day cycles)
Trial: 38211606
Drug: Subtyping-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subtyping-based therapy
Trial: 38211725
Drug: CoCM plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoCM plus Written Exposure Therapy (CoCM+WET)
Trial: 38212127
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of low-dose nivolumab (10 mg, every 2 weeks) plus intratumoral administration of 10 mg ipilimumab and 50 µg AS01
Trial: 38212206
Drug: Real-world clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real-world clinical practice (RWCP) therapy
Trial: 38212321
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of DHES0815A
Trial: 38212769
Drug: DNTGF-βR armored
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNTGF-βR armored CAR-T cell therapy
Trial: 38212823
Drug: Usual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual therapy (UT) without BBT
Trial: 38212837
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning (ML) model called IDoser for FSH dosing
Trial: 38212837
Drug: Standard practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard practice FSH dosing determined by clinician
Trial: 38212847
Drug: Daily yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily yogurt consumption (5 oz) for 8 weeks
Trial: 38212851
Drug: Multidimensional individually
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multidimensional individually tailored intervention including Norwegian Psychomotor Physiotherapy (NPMP), cognitive behavioural therapy, and a rehabilitation plan